{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mustafi S"],"funding":["Bankhead Coley Cancer Research Program","Flight Attendant Medical Research Institute","NEI NIH HHS","University of Miami Sylvester Comprehensive Cancer Center","NINDS NIH HHS","NCI NIH HHS","NIH"],"pagination":["201-210"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6557781"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43"],"pubmed_abstract":["<h4>Background</h4>Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC). However, BETi are plagued by a narrow therapeutic window as manifested by severe toxicities at effective doses. Therefore, it is a limitation to their clinical implementation in patient care.<h4>Methods</h4>The impact of vitamin C on the efficacy of small compounds including BETi was assessed by high-throughput screening. Co-treatment of TNBC by BETi especially JQ1 and vitamin C was evaluated in vitro and in vivo.<h4>Findings</h4>High-throughput screening revealed that vitamin C improves the efficacy of a number of structurally-unrelated BETi including JQ1, I-BET762, I-BET151, and CPI-203 in treating TNBC cells. The synergy between BE"],"journal":["EBioMedicine"],"pubmed_title":["Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer."],"pmcid":["PMC6557781"],"funding_grant_id":["R21CA191668","T32 EY023194","7BC10","1R56AG061911","R21 CA191668","R01 NS089525"],"pubmed_authors":["Camarena V","Huff TC","Sant DW","Brothers SP","Yoon H","Volmar CH","Zheng L","Mustafi S","Qureshi R","Wang G","Wahlestedt C","Slingerland J"],"additional_accession":[]},"is_claimable":false,"name":"Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.","description":"<h4>Background</h4>Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC). However, BETi are plagued by a narrow therapeutic window as manifested by severe toxicities at effective doses. Therefore, it is a limitation to their clinical implementation in patient care.<h4>Methods</h4>The impact of vitamin C on the efficacy of small compounds including BETi was assessed by high-throughput screening. Co-treatment of TNBC by BETi especially JQ1 and vitamin C was evaluated in vitro and in vivo.<h4>Findings</h4>High-throughput screening revealed that vitamin C improves the efficacy of a number of structurally-unrelated BETi including JQ1, I-BET762, I-BET151, and CPI-203 in treating TNBC cells. The synergy between BE","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-04T22:09:09.662Z","creation":"2019-07-24T07:13:52Z"},"accession":"S-EPMC6557781","cross_references":{"pubmed":["30975544"],"doi":["10.1016/j.ebiom.2019.04.006"]}}